| 0.5002 -0.011 (-2.19%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.76 |
1-year : | 0.92 |
| Resists | First : | 0.65 |
Second : | 0.79 |
| Pivot price | 0.53 |
|||
| Supports | First : | 0.44 | Second : | 0.36 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.57 |
| MA(100) : | 0.78 |
MA(250) : | 0.9 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.1 |
D(3) : | 25 |
| RSI | RSI(14): 31.4 |
|||
| 52-week | High : | 1.32 | Low : | 0.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ONCY ] has closed above bottom band by 29.8%. Bollinger Bands are 0.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.52 - 0.52 | 0.52 - 0.52 |
| Low: | 0.49 - 0.5 | 0.5 - 0.5 |
| Close: | 0.5 - 0.5 | 0.5 - 0.51 |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Wed, 21 Oct 2026
Oncolytics Biotech Inc. (ONCY) Interactive Stock Chart - Yahoo! Finance Canada
Tue, 20 Oct 2026
Oncolytics Biotech Inc. (ONCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 20 Oct 2026
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Tue, 20 Oct 2026
Oncolytics Biotech Inc. (ONCY) stock price, news, quote and history - Yahoo Finance Singapore
Tue, 20 Oct 2026
Stocks in play: Oncolytics Biotech Inc - Yahoo! Finance Canada
Tue, 20 Oct 2026
Oncolytics Biotech (ONCY) to Present REO 033 Trial Data at ESMO Congress 2026 - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 131 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 7,370 (K) |
| Shares Short P.Month | 7,800 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -211.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.43 |
| PEG Ratio | 0 |
| Price to Book value | -10.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|